CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. in the Healthcare sector is trading at $2.27 with a market capitalization of $732M. Wall Street consensus targets $12.25 (8 analysts), implying a +440.8% move over the next 12 months. The stock is currently near its 52-week low of $2.27, remaining 43.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.